Background: Breast cancer is a type of cancer that has a high prevalence, can occur in men and women C,,tokines are factors that are knora? to have good properties of tumor groMh and tumor inhibitory effects. Cyokine has an important role in the control ofthe immune system. development ofbreast carcinoma is closely related to mRNAexpression of IL-6 as pro-inflammatory cytokine and mRNA expression oflL-10 as antiinflammatory cltokine. Purpose: Examine changes in mRNA expression of proinflammatory cytokine and antiinflammatory cytokine in breast cancer patients with or without chemotherapy. Method: This is a case-control study, 12 subjects with breast cancer with chemotherapy as case group and 12 subjects with breast cancer without chemotherapy as control group. ln this study we using PCR and RFI,P techniques to detect polymorphisms in IL-6 and IL-10 gene. Results: In RFLP analysis, found that IL-6 and IL-10 gene were not polymorphic in all subjects for both case and control groups. Mean value of IL-6 mRNA on breast canc€r patients without receiving chemotheraphy was 10.84+0.48 whereas on breast cancer patients with chemotherapy was 6.28+1.19. Mean value ofIL-10 mRNA on breast cancer patients without receiving chemotheraphy was 6.76+0.81 whereas on breast cancer palients with chemotherapy was 9.81+l.07. The mean value of IL-6 rhRNA on breast cancer patients without receiving chemotheraphy was statistically signihcant higher than in patients with chemotheraphy. In contrast, mean value of IL-I0 mRNA on breast cancer patients without receiving chemotheraphy was statistically significant lower than in patients with chemotherapy. Conclusion: Combination of chemotherapy docetaxel, adriamycin, cyclophosphamide cause a decrease in mRNA expression of lL-6 and an increase in the expression of mRNA of IL-10 in patients with breast cancer.
Introduction
Breast cancer is a type of cancer that has a high prevalence in the world . lt is estimated that in 2012 the world's incident 1,676,633 cases wirh mortality 521,817. ln Asia Pacific region estimated 403,876 cases of breast cancer with a mortality rate of 115,863. ln Southeast Asia estimated 107,545 cases with a mortality ftte 42,003. In Indonesia 48.998 cases of breast cancer with a mortality rate 19.750 [1] .
Breast cancer is a heterogeneous disease with numerous genetic, molecular and cellular characteristics t2l Interleukins play a major role in many solid cancers pathogenesis. Polymorphisms in interleukins genes are thought to influence the expression or ftnction of these proteins and many have been evaluated for their role in inflammatory disease and cancer predisposition [3] .
Interleukins are regulatory proteins that modulates immune response by stimulating or inhibiting the activation, proliferatiorl and/or diferentiation of target cells. Different lnterleukins are known to have diverse role in breast cancer initiation and progression [4] .
Elevated interleukin 6 (IL-6) and interleukin l0 (L-10) serum concentration, are strongly associated with breast cancer and correlate with clinical stage of disease. lnterleukins may stimulate cancer cells growth and contribute to locoregional relapse as well as metastasis [5] .
The interleukin-6 (IL-6) plavs an important role in the process of inflamm ^tion, partiulady in the transition from acute to chronic inflammation. In breast cancer, IL-6 has b€en shown to inhibit the growth of cancer cells but promote the development of metastases [6] [7] . Interleukin-I0 is a multifunctional cytokine with both immunosuppressive and antiangiogenic functions. Intedeukin 10 is a potent immunoregulatory cytokine. Ir inhibits some cell functions, including T-helper (Thl) cell activity, and stimulates other functions such as a natural killer (NK) activity [8] .
Polymorphisms in the IL-10 gene promoter genetically determine the differences in IL-10 production [9] [8] .
Interleukin-10 is an immunosuppressive cytokine which responsible for development of canc€r by suppo.ting tunor escape from the immune respons€ [0]. Interleukin-10 may be regulated by a complex monoctte and macrophagederived c)'tokine network and an impairment of the immune system can be observed in neoplastic disease [1] . were used IL6 F: 5'-GGAGTCACACACTCCACCT-3' and IL6 R: 5'-CTGATTCTGAAACCTTATTAG-3' with enzyme restriction is Nla IlL Primer set for IL [0 gene were use ILlo F: 5'-CTCACTATAAA,A,T{TAGAGACGG -3); IL10 R : C (5'-CTGGCTTCCTACAGG-3) allel; ILl0 R : A (5'-GAC TC'CTCTTCCTACAGT-3') allel with restriction enzyme Ssp I.
All PCR product were run in lo% agarose gel electrophoresis and visualized by ultraviolet light. was 38 years and maximum was 67 years old, the mean age of subjects in this research was 52.5 years. Within 24 subject in this research there were l7 subject found in stage III (A / B) and 7 patients with stage IV. In RFLP analysis, found that IL-6 and IL-10 gene were not polymorphic in all subject for both case and control groups. Figure 5 shows the mean of IL-6 mRNA expression was lower in breast cancer patients who have received chemotherapy compared to the mean mRNA expression of IL-6 in breast cancer patients without chemotherapy. Figure 6 shows the mean IL-10 mRNA expression was higher in patients who have received chemotherapy than the mean of nRNA expression of IL-10 in breast canc€r patients without ch€motherapy.
Mean value of IL-6 mRNA on breast cancer patients without receiving chemotheraphy was 10.84*0.48 whereas on breast cancer patients with chemotherapy was 6.28+1.19 shown in table L Mean value of IL-10 mRNA on breast cancer patients without rec€iving chemotheraphy was 6.76+0.81 whereas on breast cancer patients with chemotherapy was 9.81+1.07 shown in table L The mean value of IL-6 mRNA on breasl canc€r patients without receiving chemotheraphy was statistically significant higher than in patients with chemotheraphy (p<0.001). In contrast, mean value of IL-I 0 rnRNA on breast cancer patients without receiving chemotheraphy was statistically significant lower than in patients with chemotherapy (p<0.001). The magnitude ofthe difference in average nRNA expression of IL-6 was 4.84 or mRNA expression of IL-6 in the chemotherapy group had 43.8 % lower than the group without chemotherapy (Table l) The magnitude of the difference in average mRNA expression of IL-l0 was 3.05 or mRNA expression of IL-10 in the chemotherapy group had 45.3 9/o highet than the group without chemotherapy (Table   r) . Breast Cancer patients cancer cell prolit-eration and gowth are reduced after treatment. This study supported by other study on prostate cancer, reported that significant association between high IL-6 in sera of prostate cancer patients and decreased response to docetaxel [23] .
In this study, mean value of IL-10 mRNA on breast cancer patients without receiving chemotheraphy was statistically significant lower than in patients with received chemotherapy.
Interleukin 10 is a potent cytokine, inhibits some cell functions, including T-helper cell activity and stimulates natural killer activity. In a murine model study suggested that IL-10 has antitumor and antimetastitic properties in mice, possible use of IL-10 in the treatment of human metastatic cancers [8] . Study on Interleukin-12 and interleukin-10 production by mononuclear phagocytic cells from breast cancer patients show that mononuclear cells of patients aflbcted by breast cancer have a defbctive IL-12 production capability while generating higher amounts of IL-10 [ l].
In this study we concluded that combination of chemotherapy docetaxel, adriamycin, cyclophosphamide cause a decrease in mRNA expression of IL-6 and an increase in the expression of mRNA of IL-l0 in patients with [20]
[2 l] [22] 
